AstraZeneca, a top 50 big pharma company has entered into a strategic pharma partners partner agreement with Charles River Laboratories for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).
The three-year pharma partners agreement extends into 2015.
James C. Foster, Chairman, President and Chief Executive Officer of Charles River said, “We are extremely pleased that AstraZeneca selected Charles River as its strategic in vivo biology partner.
Utilizing our capabilities will enable AstraZeneca to create a flexible research platform to deliver innovative health solutions. Our shared passion for scientific excellence is a strong foundation for this relationship, and we look forward to working with AstraZeneca’s scientists ‘on the same side of the table’ to achieve their drug development goals.”
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Related reports: Bigpharma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity